Zhihui Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhihui Liu has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Carol J. Thiele
Cell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA
46 shared publications - Jack F. Shern
Pediatric Oncology Branch, National Cancer Institute, Bethesda, USA
32 shared publications - Man Xu
Pediatric Oncology Branch, National Cancer Institute, Bethesda, USA
32 shared publications - Xiyuan Zhang
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
31 shared publications - Haiyan Lei
Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
30 shared publications - Ming Sun
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
30 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Table S1 shows primer sequences used for realtime PCR and HAND2 mutant sequence information.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Table S1 shows primer sequences used for realtime PCR and HAND2 mutant sequence information.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Table S5 shows genes regulated by HAND2 or MYCN in LAN5 cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Table S5 shows genes regulated by HAND2 or MYCN in LAN5 cells.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Table S7 shows HAND2 directly activated and repressed genes.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Table S7 shows HAND2 directly activated and repressed genes.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Table S2 shows sequence information of the siRNAs and sgRNAs.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Table S2 shows sequence information of the siRNAs and sgRNAs.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Table S6 shows super-enhancers associated genes identified in siCtrl cells and siHAND2 cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Table S6 shows super-enhancers associated genes identified in siCtrl cells and siHAND2 cells.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Supplementary file contains 6 supplementary figures.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Supplementary file contains 6 supplementary figures.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Table S8 shows genes altered after silencing both HAND2 and MYCN.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Table S8 shows genes altered after silencing both HAND2 and MYCN.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Table S4 shows genes regulated by HAND2 or MYCN in IMR32 cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Table S4 shows genes regulated by HAND2 or MYCN in IMR32 cells.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Table S3 shows list of antibodies used in western blot and ChIP-seq.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Table S3 shows list of antibodies used in western blot and ChIP-seq.
- Open Access
- 24 April 2025
- Published by Springer Nature in Oncogenesis
- Vol. 14 (1) , 1-13
MYCN and KAT2A form a feedforward loop to drive an oncogenic transcriptional program in neuroblastoma
The oncoprotein MYCN drives malignancy in various cancer types, including neuroblastoma (NB). However, our understanding of the mechanisms underlying its transcriptional activity and oncogenic function, as well as effective strategies to target it, remains limited. We discovered that MYCN interacts with the transcriptional coactivator KAT2A, and this interaction significantly contributes to MYCN’s activity in NB. Our genome-wide analyses indicate MYCN recruits KAT2A to bind to DNA, thereby transcriptionally regulating genes associated with ribosome biogenesis and RNA processing. Moreover, we identified that MYCN directly activates KAT2A transcription, while KAT2A acetylates MYCN, increasing MYCN protein stability. Consequently, MYCN and KAT2A establish a feedforward loop that effectively regulates global gene expression, governing the malignant NB phenotype. Treatment of NB cells with a KAT2A Proteolysis Targeting Chimera (PROTAC) degrader reduces MYCN protein levels, antagonizes MYCN-mediated gene transcription regulation and suppresses cell proliferation. This study highlights the potential of transcriptional cofactors as viable targets for developing anti-MYCN therapies.
- 24 April 2025
- Published by Springer Nature in Oncogenesis
- Vol. 14 (1) , 1-13
Open AccessMYCN and KAT2A form a feedforward loop to drive an oncogenic transcriptional program in neuroblastoma
The oncoprotein MYCN drives malignancy in various cancer types, including neuroblastoma (NB). However, our understanding of the mechanisms underlying its transcriptional activity and oncogenic function, as well as effective strategies to target it, remains limited. We discovered that MYCN interacts with the transcriptional coactivator KAT2A, and this interaction significantly contributes to MYCN’s activity in NB. Our genome-wide analyses indicate MYCN recruits KAT2A to bind to DNA, thereby transcriptionally regulating genes associated with ribosome biogenesis and RNA processing. Moreover, we identified that MYCN directly activates KAT2A transcription, while KAT2A acetylates MYCN, increasing MYCN protein stability. Consequently, MYCN and KAT2A establish a feedforward loop that effectively regulates global gene expression, governing the malignant NB phenotype. Treatment of NB cells with a KAT2A Proteolysis Targeting Chimera (PROTAC) degrader reduces MYCN protein levels, antagonizes MYCN-mediated gene transcription regulation and suppresses cell proliferation. This study highlights the potential of transcriptional cofactors as viable targets for developing anti-MYCN therapies.